|
ES2586580T3
(es)
|
2010-07-06 |
2016-10-17 |
Glaxosmithkline Biologicals Sa |
Inmunización de mamíferos grandes con dosis bajas de ARN
|
|
HUE026646T2
(en)
|
2010-07-06 |
2016-07-28 |
Glaxosmithkline Biologicals Sa |
Preferred liposomes containing lipids of PKA value for delivery of RNA
|
|
HRP20161352T1
(hr)
|
2010-07-06 |
2016-12-02 |
Glaxosmithkline Biologicals Sa |
Čestice nalik na virione za unos samoreplicirajućih molekula rna
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DK4226941T3
(da)
|
2010-08-31 |
2024-12-02 |
Glaxosmithkline Biologicals Sa |
Pegylerede liposomer til levering af immunogen-kodende rna
|
|
EP4043040B1
(en)
|
2010-08-31 |
2023-01-11 |
GlaxoSmithKline Biologicals SA |
Small liposomes for delivery of immunogen-encoding rna
|
|
CA2821992A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
KR102266691B1
(ko)
*
|
2010-10-11 |
2021-06-23 |
노파르티스 아게 |
항원 전달 플랫폼
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
JP6184945B2
(ja)
|
2011-06-08 |
2017-08-23 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
mRNA送達のための脂質ナノ粒子組成物および方法
|
|
US11896636B2
(en)
|
2011-07-06 |
2024-02-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic combination compositions and uses thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
HRP20220250T1
(hr)
|
2011-10-03 |
2022-04-29 |
Modernatx, Inc. |
Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
|
|
SI2791160T1
(sl)
|
2011-12-16 |
2022-07-29 |
Modernatx, Inc. |
Sestave modificirane MRNA
|
|
AU2013243952A1
(en)
|
2012-04-02 |
2014-10-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
IN2014KN02929A
(enExample)
|
2012-07-06 |
2015-05-08 |
Novartis Ag |
|
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
|
SMT202200337T1
(it)
|
2012-11-26 |
2022-09-14 |
Modernatx Inc |
Rna modificato al livello del terminale
|
|
HK1214962A1
(zh)
|
2013-01-10 |
2016-08-12 |
Seqirus UK Limited |
流感病毒免疫原性组合物及其应用
|
|
EP2968391A1
(en)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
EP3083556B1
(en)
*
|
2013-12-19 |
2019-12-25 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
ES2844208T3
(es)
|
2014-03-25 |
2021-07-21 |
Univ Yale |
Usos de los factores inhibidores de la migración de macrófagos parásitos
|
|
US9968555B2
(en)
|
2014-04-08 |
2018-05-15 |
Aradigm Corporation |
Liposomal formulations that form drug nanocrystals after freeze-thaw
|
|
JP2017510662A
(ja)
|
2014-04-08 |
2017-04-13 |
アラダイム コーポレーション |
非結核性抗酸菌に対する活性を有するリポソームシプロフロキサシン製剤
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
EP2974739A1
(en)
|
2014-07-15 |
2016-01-20 |
Novartis AG |
RSVF trimerization domains
|
|
WO2016011226A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
CA2998810A1
(en)
|
2015-09-17 |
2017-03-23 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA2999916C
(en)
|
2015-09-23 |
2021-07-20 |
Massachusetts Institute Of Technology |
Compositions and methods for modified dendrimer nanoparticle vaccine delivery
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
EP4349405A3
(en)
|
2015-10-22 |
2024-06-19 |
ModernaTX, Inc. |
Respiratory virus vaccines
|
|
ES2924407T3
(es)
|
2015-12-10 |
2022-10-06 |
Modernatx Inc |
Composiciones y procedimientos para el suministro de agentes terapéuticos
|
|
SMT202200252T1
(it)
|
2015-12-22 |
2022-07-21 |
Modernatx Inc |
Composti e composizioni per il rilascio intracellulare di agenti
|
|
WO2017123315A2
(en)
*
|
2016-01-12 |
2017-07-20 |
Aradigm Corporation |
Nanocrystals formed in a microenvironment
|
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
AU2017268394A1
(en)
|
2016-05-18 |
2019-01-03 |
Modernatx, Inc. |
Polynucleotides encoding relaxin
|
|
US10967057B2
(en)
|
2016-06-02 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Zika viral antigen constructs
|
|
WO2017220099A1
(en)
|
2016-06-24 |
2017-12-28 |
Statens Serum Institut |
Adjuvants with modified drainage properties
|
|
EP3518966A1
(en)
|
2016-09-29 |
2019-08-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3538146A4
(en)
|
2016-11-11 |
2020-07-15 |
ModernaTX, Inc. |
INFLUENZA VACCINE
|
|
EP4043031A3
(en)
|
2016-11-17 |
2022-11-23 |
GlaxoSmithKline Biologicals SA |
Zika viral antigen constructs
|
|
CN110505877A
(zh)
*
|
2017-02-01 |
2019-11-26 |
摩登纳特斯有限公司 |
Rna癌症疫苗
|
|
EP3596041B1
(en)
|
2017-03-15 |
2022-11-02 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
Respiratory syncytial virus vaccine
|
|
AU2018234828A1
(en)
|
2017-03-15 |
2019-09-19 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
AU2018234814B2
(en)
|
2017-03-15 |
2022-06-30 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
|
JP2020518648A
(ja)
|
2017-05-08 |
2020-06-25 |
グリットストーン オンコロジー インコーポレイテッド |
アルファウイルス新生抗原ベクター
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
AU2018298422B2
(en)
|
2017-07-04 |
2023-04-06 |
CureVac SE |
Novel nucleic acid molecules
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
US11744801B2
(en)
*
|
2017-08-31 |
2023-09-05 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
CA3075549A1
(en)
|
2017-09-13 |
2019-03-21 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for reprogramming somatic cells
|
|
US20200283497A1
(en)
|
2017-09-13 |
2020-09-10 |
Biontech Cell & Gene Therapies Gmbh |
Rna replicon for expressing at cell receptor or an artificial t cell receptor
|
|
EP3461497A1
(en)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Viral antigens
|
|
CN111954519A
(zh)
*
|
2017-12-06 |
2020-11-17 |
新南创新私人有限公司 |
用于药物递送的脂质体系统
|
|
BR112020013679A2
(pt)
|
2018-01-04 |
2020-12-01 |
Iconic Therapeutics, Inc. |
anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados
|
|
CA3109165A1
(en)
|
2018-08-17 |
2020-02-20 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061284A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
JP7640452B2
(ja)
|
2018-09-19 |
2025-03-05 |
モデルナティエックス インコーポレイテッド |
高純度peg脂質及びそれらの使用
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
CN113166783B
(zh)
|
2018-10-09 |
2024-10-11 |
不列颠哥伦比亚大学 |
包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
WO2020144295A1
(en)
|
2019-01-10 |
2020-07-16 |
Biontech Rna Pharmaceuticals Gmbh |
Localized administration of rna molecules for therapy
|
|
AR119705A1
(es)
*
|
2019-03-29 |
2022-01-05 |
Glycomine Inc |
Formulaciones liposomales y sus métodos de uso y preparación
|
|
AU2020282369A1
(en)
|
2019-05-30 |
2022-01-20 |
Seattle Project Corp. |
Modified adenoviruses
|
|
US20220305117A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
|
JP2022536850A
(ja)
|
2019-06-18 |
2022-08-19 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
B型肝炎ウイルス(hbv)ワクチンおよび抗pd-1または抗pd-l1抗体の組合せ
|
|
MA56533A
(fr)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Co |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
|
|
CA3141323A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Recombinant interleukin 12 construct and uses thereof
|
|
EP3986563A1
(en)
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
|
KR20220035457A
(ko)
|
2019-07-21 |
2022-03-22 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
치료 바이러스 백신
|
|
US11066355B2
(en)
|
2019-09-19 |
2021-07-20 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP3819377A1
(en)
|
2019-11-08 |
2021-05-12 |
Justus-Liebig-Universität Gießen |
Circular rna and uses thereof for inhibiting rna-binding proteins
|
|
PH12022551208A1
(en)
|
2019-11-18 |
2023-04-24 |
Janssen Biotech Inc |
Vaccines based on mutant calr and jak2 and their uses
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
EP3865122A1
(en)
*
|
2020-02-11 |
2021-08-18 |
Pantherna Therapeutics GmbH |
Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium
|
|
US11759515B2
(en)
|
2020-03-09 |
2023-09-19 |
Arcturus Therapeutics, Inc. |
Compositions and methods for inducing immune responses
|
|
AU2021244555A1
(en)
|
2020-03-24 |
2022-11-24 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
IL296662A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
EP4135761A1
(en)
|
2020-04-16 |
2023-02-22 |
GlaxoSmithKline Biologicals S.A. |
Sars cov-2 spike protein construct
|
|
CA3179444A1
(en)
*
|
2020-05-20 |
2021-11-25 |
Avak Kahvejian |
Immunogenic compositions and uses thereof
|
|
JP7769644B2
(ja)
|
2020-06-04 |
2025-11-13 |
バイオエヌテック エスエー |
多用途かつ効率的な遺伝子発現のためのrnaレプリコン
|
|
EP4161570A1
(en)
|
2020-06-05 |
2023-04-12 |
GlaxoSmithKline Biologicals S.A. |
Modified betacoronavirus spike proteins
|
|
WO2022002783A1
(en)
|
2020-06-29 |
2022-01-06 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
IL299571A
(en)
|
2020-07-08 |
2023-02-01 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
CA3189338A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
WO2022023284A1
(en)
|
2020-07-27 |
2022-02-03 |
Anjarium Biosciences Ag |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
WO2022032196A2
(en)
|
2020-08-06 |
2022-02-10 |
Gritstone Bio, Inc. |
Multiepitope vaccine cassettes
|
|
WO2022036170A1
(en)
|
2020-08-14 |
2022-02-17 |
Arcturus Therapeutics, Inc. |
Method of lyophilizing lipid nanoparticles
|
|
EP4008785A1
(en)
|
2020-12-03 |
2022-06-08 |
Justus-Liebig-Universität Gießen |
Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses
|
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|
|
US11918643B2
(en)
|
2020-12-22 |
2024-03-05 |
CureVac SE |
RNA vaccine against SARS-CoV-2 variants
|
|
US20240301006A1
(en)
|
2020-12-23 |
2024-09-12 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna
|
|
US20240316090A1
(en)
|
2020-12-28 |
2024-09-26 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
EP4032546A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
WO2022200575A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
EP4321504A4
(en)
*
|
2021-04-08 |
2024-10-09 |
Xiamen Sinopeg Biotech Co., Ltd. |
PEGYLATED LIPID AND LIPOSOME THUS MODIFIED, PHARMACEUTICAL COMPOSITION COMPRISING A LIPOSOME, ASSOCIATED PREPARATION AND USE
|
|
CA3214538A1
(en)
|
2021-04-20 |
2022-10-27 |
Joel DE BEER |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
WO2022232289A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
US20240285755A1
(en)
|
2021-05-24 |
2024-08-29 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
EP4352247A1
(en)
|
2021-06-09 |
2024-04-17 |
GlaxoSmithKline Biologicals s.a. |
Release assay for determining potency of self-amplifying rna drug product and methods for using
|
|
EP4387597A1
(en)
|
2021-08-16 |
2024-06-26 |
GlaxoSmithKline Biologicals SA |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
EP4387596A1
(en)
|
2021-08-16 |
2024-06-26 |
GlaxoSmithKline Biologicals SA |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
EP4396355A1
(en)
|
2021-09-03 |
2024-07-10 |
GlaxoSmithKline Biologicals S.A. |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
CA3234214A1
(en)
|
2021-10-18 |
2023-04-27 |
BioNTech SE |
Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
|
|
JP2024539087A
(ja)
|
2021-10-18 |
2024-10-28 |
バイオエヌテック エスエー |
修飾複製可能rnaおよび関連組成物ならびにそれらの使用
|
|
EP4430024A1
(en)
|
2021-11-08 |
2024-09-18 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP4463475A2
(en)
|
2022-01-14 |
2024-11-20 |
Anjarium Biosciences AG |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
WO2023213378A1
(en)
|
2022-05-02 |
2023-11-09 |
BioNTech SE |
Replicon compositions and methods of using same for the treatment of diseases
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
CA3258303A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Compositions of lipid nanoparticles and their uses
|
|
CN119604304A
(zh)
|
2022-06-18 |
2025-03-11 |
葛兰素史克生物有限公司 |
包含非翻译区或编码来自严重急性呼吸道冠状病毒2奥密克戎毒株刺突蛋白的区段的重组rna分子
|
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
CA3267295A1
(en)
|
2022-09-15 |
2024-03-21 |
TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH-Aysegul YILDIZ |
SYSTEMS AND COMPOSITIONS CONTAINING TRANS-AMPLIFYING RNA VECTORS WITH MIARN
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
DE202023106198U1
(de)
|
2022-10-28 |
2024-03-21 |
CureVac SE |
Impfstoff auf Nukleinsäurebasis
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
JP2025537178A
(ja)
|
2022-11-08 |
2025-11-14 |
オーナ セラピューティクス, インコーポレイテッド |
環状rna組成物
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
EP4626400A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
IL320870A
(en)
|
2022-12-01 |
2025-07-01 |
Generation Bio Co |
Lipid nanoparticles containing nucleic acids, ionizable lipids, sterols, lipid-anchored polymers and auxiliary lipids and their uses
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
CN121001738A
(zh)
|
2023-04-27 |
2025-11-21 |
葛兰素史克生物有限公司 |
流感病毒疫苗
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
WO2025040709A1
(en)
|
2023-08-24 |
2025-02-27 |
BioNTech SE |
Systems and compositions comprising highly active trans-amplifying replicases
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025051381A1
(en)
|
2023-09-08 |
2025-03-13 |
BioNTech SE |
Methods and compositions for localized expression of administered rna
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|